CoreRx, a leader in early drug contract development, has expanded manufacturing capabilities to include 15-cubic foot and 30-cubic foot V-shell blenders, a 43-station high speed tablet press, high speed encapsulation and a 40-inch solvent-capable coating pan. The additional equipment train will allow for increased clinical batch sizes in support of growing client demand.  The additional equipment will allow CoreRx scientists to manufacture batch sizes of up to one million solid dosage units per day.

CoreRx continues to grow in 2010, providing unsurpassed contract pharmaceutical development services to the pharma & biotech industries. This is more evident with the latest announcement of the Tampa Bay Business Journal announcement of the Fast 50 nominees.

http://www.interphex.com/en/Home/?campaignid=61545716&iusercampaignid=60816755

SoluBest, Ltd, today announced an agreement to license its proprietary nanotechnology platform for significantly improving the bio-performance of poorly soluble and insoluble drugs to CoreRx, Inc., an innovative contract formulation company. SoluBest’s Solumer™ technology is extremely versatile, as it can be applied to a wide range of pharmaceuticals. The license agreement will provide CoreRx with access to Solumer™ technology and the rights to apply the technology to client’s drug candidates currently in clinical development.

Common “First in Man” approaches vs. The Lost Art of Formulation Development

In today’s market, pharmaceutical and biotech companies are being asked to do more…with less.  Diminishing resources, pipelines, competition, and increased regulatory hurdles are forcing us to rethink our strategy. We must work smarter, not harder.